OncoMatch/Clinical Trials/NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Is NCT05919264 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for cancer.
Treatment: FOG-001 · mFOLFOX-6 · Nivolumab · Trifluridine/tipiracil · Bevacizumab — The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Colorectal Cancer
Tumor Agnostic
Hepatocellular Carcinoma
Prostate Cancer
Endometrial Cancer
Biomarker criteria
Required: APC loss-of-function mutation
Participants with tumors known to be negative for APC LoF mutations ... are not eligible
Required: CTNNB1 gain-of-function mutation
Participants with tumors known to be negative for ... CTNNB1 GoF mutations ... are not eligible
Disease stage
Required: Stage III, IV
Diagnosis of treatment-refractory advanced/metastatic solid tumor; locally advanced or metastatic non-MSI-H or non-dMMR CRC
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Unstable/inadequate cardiac function excluded
Adequate organ and marrow function. Unstable/inadequate cardiac function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Honor Health · Scottsdale, Arizona
- Arizona Cancer Center at University of Arizona · Tucson, Arizona
- Stanford Cancer Institute, Stanford University · Palo Alto, California
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center · San Francisco, California
- Sarcoma Oncology Center · Santa Monica, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05919264 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require APC?
Yes, APC loss-of-function mutation is a required biomarker for enrollment.
Does this trial require CTNNB1?
Yes, CTNNB1 gain-of-function mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify